SCHEMBL4687582

SCHEMBL4687582

COc1ccc(N2Cc3cnc(N(C(=O)OCOC(=O)CN(C)C)c4ccccc4)nc3N(c3ccccc3)C2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 9/20 0.40
EGFR P00533 8/20 0.39
FGFR1 P11362 4/20 0.39
PDGFRB P09619 3/20 0.39
PDGFRA P16234 3/20 0.39
FGFR2 P21802 3/20 0.39
FGFR3 P22607 3/20 0.39
KDR P35968 3/20 0.39
FYN P06241 2/20 0.39
MAPK1 P28482 2/20 0.39
EPHB3 P54753 2/20 0.39
USP2 O75604 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 2/20 0.33
PRKACA P17612 1/20 0.33
PRKACG P22612 1/20 0.33
PRKACB P22694 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4686796 0.92 FGFR4 (0.40) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL14291681 0.90 FGFR4 (0.41) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL6706739 0.88 FGFR4 (0.41) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4785400 0.87 FGFR4 (0.45) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4785398 0.86 FGFR4 (0.44) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4686744 0.85 FGFR4 (0.45) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4692720 0.85 FGFR4 (0.44) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4689939 0.85 FGFR4 (0.44) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4689961 0.84 FGFR4 (0.42) FGFR4EGFRFGFR1PDGFRBPDGFRA
SCHEMBL4689703 0.83 FGFR4 (0.44) FGFR4EGFRFGFR1PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556384-B1 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY HOFFMANN LA ROCHE (CH) 2008-02-20 EP claimed
US-7084270-B2 Pyrimido compounds having antiproliferative activity HOFFMAN-LA ROCHE INC. (US) 2006-08-01 US claimed
US-20040038995-A1 Pyrimido compounds having antiproliferative activity CHEN YI (US) 2004-02-26 US claimed
EP-1556384-B1 PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY HOFFMANN LA ROCHE (CH) 2008-02-20 EP disclosed
US-7084270-B2 Pyrimido compounds having antiproliferative activity HOFFMAN-LA ROCHE INC. (US) 2006-08-01 US disclosed
US-20040038995-A1 Pyrimido compounds having antiproliferative activity CHEN YI (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038995-A1 Pyrimido compounds having antiproliferative activity LCK, FGFR1, FGFR3 FGFR4 5/4885EGFR 45/4885FGFR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.